muscarinic


Also found in: Medical, Encyclopedia, Wikipedia.

mus·ca·rine

 (mŭs′kə-rēn′)
n.
A highly toxic alkaloid, C9H20NO2, found in fly agaric and certain other mushrooms. When ingested, it binds to acetylcholine receptors and thus stimulates the parasympathetic nervous system.

[New Latin muscāria, specific epithet (from feminine of Latin muscārius, of flies, from musca, fly) + -ine.]

mus′ca·rin′ic (-rĭn′ĭk) adj.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

muscarinic

(ˌmʌskəˈrɪnɪk)
adj
1. (Physiology) of, relating to or resembling muscarine or its physiological action
2. (Physiology) (of a receptor) able to respond to muscarine
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
References in periodicals archive ?
KarXT, a proprietary oral modulator of muscarinic receptors, is the Company's lead product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the central nervous system (CNS).
That approach came as news to many meeting attendees, based on results of an audience poll in which 76% of attendees picked triple therapy for a 65-year-old male with COPD and frequent exacerbations who was taking only a long-acting muscarinic antagonist (LAMA).
That approach came as news to many internists, at least going by results of an audience poll in which 76% of attendees picked triple therapy for a 65-year-old male with COPD and frequent exacerbations despite having used a long-acting muscarinic antagonist (LAMA).
Karuna Pharmaceuticals, a clinical-stage pharmaceutical company, targets muscarinic cholinergic receptors for the treatment of Central Nervous System disorders.
The products are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Ultibro Breezhaler is an inhaled once-daily fixed-dose combination of indacaterol (a long-acting beta 2 agonist; LABA) and glycopyrronium bromide (a long-acting muscarinic antagonist; LAMA) and Seebri Breezhaler is an inhaled fixed-dose formulation of glycopyrronium bromide (a long-acting muscarinic antagonist; LAMA).
The expanded indication for the once-daily single inhaler triple therapy would enable use by patients not adequately treated by a long-acting muscarinic receptor antagonist and long-acting beta2-agonist.
Long-acting muscarinic antagonists (LAMAs) is a selective M3-receptor antagonist with obvious efficiency and fewer adverse reactions.
This overstimulation of acetylcholine receptors is followed by paralysis of cholinergic synaptic transmission in the central nervous system, in autonomic ganglia at parasympathetic and some sympathetic nerve endings and in somatic nerves.7-9 The mainfestations of OPP may be classified into effects secondary to nicotinic, muscarinic and CNS receptor overstimulation.
While comparing the effect of cholinergic blocker, atropine (a muscarinic blocker) on acetylcholine-induced contractility between non-Hirschsprung and Hirschsprung's cases, it was observed that gut contractility induced by acetylcholine was blocked significantly in non-Hirschsprung's cases whereas in Hirschsprung's cases atropine failed to block the responses.